TechNavio recognizes the following companies as the key players in the Global Multiple Sclerosis (MS) Therapeutics Market: Bayer HealthCare AG, Biogen Idec Inc., Merck Serono S.A., Novartis AG, and Teva Pharmaceutical Industries Ltd.
Commenting on the report, an analyst from TechNavio’s team said: “Currently, there is an increase in the adoption of biomarkers that are 100 percent specific to RRMS conditions. The use of biomarkers proves to be a sensitive indicator of the slightest disease activity in MS patients. A highly specific protein biomarker for MS aids in quick and precise identification of patients with the disease, possibly before clinically relevant symptoms arise. Thus, the use of biomarkers helps prevent the significant neurodegeneration associated with the disease. Recently, the Global MS market has witnessed various collaborations for MS biomarkers. Regulus Therapeutics and Biogen Idec entered into a collaboration to identify blood-based microRNAs as biomarkers for MS. It is believed by both partners that microRNA biomarkers aid in the selection of ideal patient segments in clinical trials and also in monitoring disease progression or relapse.”
According to the report, one of the main drivers is the increase in the diagnosis and treatment of MS. This is because of the usage of the latest revised McDonald diagnostic criteria in the treatment of MS. The McDonald diagnostic criteria consist of a combination of clinical, imaging, and paraclinical tests used in the diagnosis of MS. This latest revision has helped in improving the detection of the symptoms of the disease. A McDonald diagnostic criterion helps improve the sensitivity from around 46 percent to 74 percent. This indirectly aids in diagnosing MS more rapidly than in the early days.
Further, the report states that one of the major challenges in the market is the lack of therapies for the management of the progressive form of the disease. The patients under this category take only symptomatic treatment to improve their quality of life.
The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are AB Science, Abbvie Inc., Active Biotech AB, AstraZeneca plc, Genzyme, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., Hoffmann-La Roche Inc., and Sanofi S.A.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit https://www.technavio.com/report/global-multiple-sclerosis-ms-therapeutic…
TechNavio, the market research platform of Infiniti Research Ltd., publishes periodic market research reports on niche and emerging technologies. For more information on our market research, please visit https://www.technavio.com/healthcare-chemicals-food-retail
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Research Report -Global Multiple Sclerosis (MS) Therapeutics Market 2012-2016
